Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
48 hedge funds and large institutions have $23.4M invested in Infinity Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
2% more funds holding
Funds holding: 47 → 48 (+1)
14% less capital invested
Capital invested by funds: $27.2M → $23.4M (-$3.82M)
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$147K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$145K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$21.7K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$16.4K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$252K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$235K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$101K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$51.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$33.9K |
INFI Hedge Fund Activity: Q1 2020 in Review
48 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q1 2020, worth a combined $23.4M — down 14% from $27.2M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new INFI positions and 3 closed out — a net gain of 3 holders — while 7 added to existing stakes and 13 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $147K. The largest seller was Platinum Investment Management, cutting an estimated $252K.
- 48 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q1 2020, up from 47 in Q4 2019.
- Funds reported $23.4M of Infinity Pharmaceuticals, Inc. stock for Q1 2020, down 14% quarter-over-quarter.
- 6 funds opened new Infinity Pharmaceuticals, Inc. positions in Q1 2020 and 3 closed out, a net change of +3 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q1 2020 was Renaissance Technologies, an estimated $147K added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q1 2020 was Platinum Investment Management, an estimated $252K sold.
Based on aggregated 13F filings for Q1 2020.